News Of The Day
Check Out The Blog For Additional News
The 66th Liver Meeting of the American Association for the Study of Liver Diseases
November 13-17 - San Francisco
AASLD - Conference Coverage
Indexed by pharmaceutical company:
Follow the links and review the latest key presentations on chronic hepatitis C coming out of this months liver meeting.
Blog - HCV New Drugs
Keeping Up With Rapid Advances in Hepatitis C Treatment
Hepatitis C - NICE publishes final drug recommendations for the treatment of four separate medical conditions
Trinity Scientists Homing in on New Hepatitis C Vaccine
HCV: 4 Weeks Too Short for Treatment With New Drugs
"In this proof-of-concept study involving treatment-naive noncirrhotic patients with chronic HCV genotype 1 infection, 4 weeks of treatment with ledipasvir, sofosbuvir, and GS-9451 with or without GS-9669 was well-tolerated; however, only 30% (15 of 50) of patients achieved [a sustained viral response at 12 weeks]," write Anita Kohli, MD, from the University of Maryland, Baltimore, and colleagues "Thus, a treatment duration of 4 weeks with 3 or 4 potent [direct-acting antivirals] is not sufficient to cure HCV infection in most patients."
AbbVie's TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection
AASLD: Hepatitis C Disease Burden in the United States in 2015 and Beyond
Incidence and Determinants of Denial of DAA Therapy by Type of Insurance During the First 6 Months of the Modern HCV Treatment Era
Expensive drugs that cure hepatitis C are worth the cost, even at early stages of liver fibrosis
It is worthwhile to give patients expensive new drugs that can cure their hepatitis C much earlier than some insurers are now willing to pay for them, according to a UC San Francisco study that models the effects of treating the disease early versus late in its development.
Lucinda K Porter, RN
Hepatitis C Highlights of the 2015 Liver Meeting
Selecting my favorite hepatitis C research presented at the recent annual meeting of the American Association for the Study of Liver Diseases (AASLD) is like picking a favorite star in the sky. There are so many to choose from and they were all beautiful. Here are the ones that dazzled me.
Exclusive HCV Interview: Lucinda K Porter, RN
Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?
Daklinza(Daclatasvir): Bristol-Myers Lets Low-Income Countries Copy Hepatitis C Pills
Bristol-Myers Squibb Co. has signed a broad agreement with Medicines Patent Pool, allowing the United Nations-backed organization to distribute licenses for generic-drug companies to copy its hepatitis C treatment in more than 100 developing and ...
Platelets promote the liver's regeneration process following surgery
A team of researchers at the MedUni Vienna has discovered that certain platelet-derived growth factors are of major significance for the liver's regeneration processes. It has been shown that platelets can encourage the regrowth of liver tissue in patients who have had parts of their liver removed surgically. This may also act as a starting point for the prediction of potential post-operative problems. The work has been published in the key journal on liver medicine, "Hepatology".
Galectin Therapeutics - Developing New Treatments For Fibrosis and Cirrhosis
ASTRAL-2: Sovaldi/velpatasvir bests standard therapy in HCV genotype 2
Liver fibrosis improves after successful treatment for hepatitis C
Hepatitis C Cure Often Leads to Improvement in Liver Health
Daklinza & Sovaldi Better Treats Those With HIV & HCV
Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and ribavirin.
High Genotype 2 and 3 Hep C Cure Rates for New AbbVie Combo
AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 posted mostly high cure rates among people with genotypes 2 and 3 of the virus.
Near-Perfect Results for New AbbVie Hep C Combo in Genotype 1s
Eight or 12 weeks of AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 cured 97 to 100 percent of people with genotype 1.
Clinicians Have Multiple First-line Options for Treating HCV; Challenge is Implementation: all patients have right to be treated
A succession of discoveries has led to infection cure rates of better than 90% in the quarter century since the discovery of the hepatitis C virus (HCV).
New England Journal Of Medicine
Sofosbuvir plus Velpatasvir for Chronic Pangenotypic HCV Infection: Phase III Results
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Here, we present the results of two randomized, controlled, phase 3 trials (ASTRAL-2 and ASTRAL-3) in which treatment with a fixed-dose combination tablet of sofosbuvir and velpatasvir for 12 weeks was compared with standard treatment with sofosbuvir plus ribavirin for 12 or 24 weeks in patients who had received prior treatment for HCV genotype 2 or 3 infection and in those who had not received such treatment, including those with compensated cirrhosis.
It's time to stop stigmatizing Hepatitis C patients and cover their treatment
The Oregon HCV Treatment Access Initiative met for the second time, and the Centers for Medicare and Medicaid Services (CMS) released a letter about increasing access for Medicaid beneficiaries to new hepatitis C Drugs
Short-Course Triple HCV Tx Has Promise in Cirrhosis
Harvoni plus vedroprevir for 8 weeks achieved high SVR rates
Watch Independent Expert Review on AASLD 2015: Discussion on HCV therapeutic options and developments
Review will feature four HCV experts reviewing and discussing key presentations on chronic hepatitis C presented at AASLD 2015.
Watch Patients Treated For Hepatitis C: Studying possible regression in cirrhosis/ fibrosis
A considerable amount of research has been done looking at how liver disease can progress in patients, but a recent study looked at possible regression in conditions like cirrhosis and fibrosis.
Reducing HCV disease burden may be possible within 6 years
SAN FRANCISCO — Current screening and treatment paradigms for hepatitis C virus may lead to a significant reduction in the disease burden within 6 years, according to findings presented at The Liver Meeting.
US calls for a ban on advertising prescription drugs
Ledipasvir/Sofosbuvir Produces Sustained Virologic Rate in Patients With Hepatitis C Genotype 1 and Cirrhosis: Presented at Liver Meeting
AASLD 2015 - The Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C
Nations Awaiting Price Break in HCV Drugs
HCV: Making it Rare in the US Will Cost $106 Billion, Study Finds
Treating HCV Patients Who Fail Direct-Acting Antivirals
All is not lost when hepatitis C Genotype 1 patients fail to benefit from treatment with direct-acting antivirals (DAAs). Reporting at the Liver Meeting (AASLD) in San Francisco, Fred Poordad, MD, of the Texas Liver Institute/ University of Texas Health Science Center in San Antonio, TX and colleagues said they had success retreating patients who had failed DAAs.
NEJM EDITORIAL: Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs
Related: Simple drug regimen cures hepatitis C virus in patients after 12 weeks - once daily drug combination of sofosbuvir-velpatasvir for a 12 week period was effective in both treatment-naïve and previously treated patients with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis (where scarring of the liver has occurred but patients have yet to experience symptoms as a result of it).
Are Adult Doses of HCV Regimens Appropriate in Adolescents?
By Debra Hughes, MS
Adult doses of sofosbuvir plus ribavirin or ledipasvir/sofosbuvir provided comparable plasma exposures and tolerable safety profile in adolescents with hepatitis C virus (HCV) infection, reported Brian Kirby, PhD, from Gilead Sciences, Foster City, CA, at The Liver Meeting® 2015.
Elbasvir/grazoprevir effectively treats patients with compensated cirrhosis
Elbasvir/grazoprevir effectively treated both experienced and naive patients with compensated cirrhosis, with an integrated analysis presented at The Liver Meeting 2015 putting forward that treatment-experienced patients may benefit from a longer treatment duration with ribavirin.
SVR associated with improvement in fibrosis, cirrhosis
SAN FRANCISCO — Sixty percent of patients who reached SVR after treatment for hepatitis C virus infection demonstrated improvement in fibrosis or cirrhosis, according to findings presented at The Liver Meeting 2015.
Liver Disease A Serious Concern in Veteran Population
Q&A With Melissa Harris From Bristol-Myers Squibb: Expanding Hepatitis C Treatment To New Genotypes And Populations VIDEO
Hepatitis C is becoming a more commonly treated condition in many of its genotypes while others continue to present problems for the pharmaceutical and medical communities. Work is being done to overcome those challenges around the world.
AASLD 2015 - Merck Announces Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy
Janssen Presents New Data Assessing OLYSIO® (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt
Pharco Reports Ravidasvir with Sofosbuvir Achieved 100% Cure Rate for Non-Cirrhotic, Genotype 4 Patients
AASLD 2015: Sofosbuvir/ Velpatasvir + GS-9857 for 8 Weeks Cures Most Genotype 1 or 3 Hepatitis C Patients
An 8-week triple combination of Gilead Sciences' sofosbuvir, velpatasvir, and GS-9857 showed a high sustained response rate in a Phase 2 study of difficult-to-treat hepatitis C patients including treatment-experienced people with HCV genotype 3 and liver cirrhosis, according to results presented at the 2015 AASLD LiverMeeting taking place this week in San Francisco. A 6-week regimen appeared inadequate, however, and more than 8 weeks may be needed for people who previously used direct-acting antivirals.
ABBVIE Announces High SVR In Phase 2 studies With Pan-Genotypic Investigational Regimen ABT-493 AND ABT-530
NORTH CHICAGO, Ill., Nov. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment (SVR12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. After 12 weeks of treatment, SVR12 rates achieved were 97-100 percent in genotype 1 (GT1), 96-100 percent in genotype 2 (GT2) and 83-94 percent in genotype 3 (GT3) patients.1,2,3 These data are being presented at The Liver Meeting® 2015, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
Patient advocacy groups protest limits of Gilead's support program
SAN FRANCISCO — At the Liver Meeting 2015, patient advocacy groups stood in protest of restrictions implemented this summer to the patient support program, demanding reinstatement of free treatment access to all patients with hepatitis C virus.
Can Coffee Help Cut Risk of HCC Recurrence?
By Bryant Furlow
Coffee consumption might reduce the risk of hepatocellular carcinoma (HCC) recurrence and improve survival following orthotopic liver transplantation (OLT), suggest study findings reported at the The Liver Meeting® 2015.
Weekend Updates: Series Of 5-minute Daily Clips From The Liver Meeting 2015
Gilead Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies at The Liver Meeting 2015
FDA - HARVONI (ledipasvir/sofosbuvir) label update
HCV NEXT November Issue - Pricing Pressures: How the Business of Medicine Affects the Price of Therapy
AASLD 2015 - Hepatitis C: an Effective Regimen for Genotype 3
Hepatitis C’s genotype 3 can be hard to cure, but researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA, said they have found a regimen that works.
HCV in Egypt: Success in Treating Genotype 4
Nov 14, 2015 | AASLD 2015 | Gale Scott
Egypt has the highest prevalence of hepatitis C in the word and most of it (90%) is genotype 4. Researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA reported success in a trial of ravidasvir
Insurance Lagging on Paying for HCV Antivirals
Nov 14, 2015 | AASLD 2015 | Gale Scott
The high costs of direct-acting antivirals to treat hepatitis C infection is no secret—but neither is the fact that the drugs are cost-effective. Pennsylvania researchers found insurers were lagging in approving payment for the drugs in their four-state region, with Medicaid programs the worst offenders.
HCV Antiviral Resistance a Challenge
Nov 14, 2015 | AASLD 2015 | Gale Scott
Despite the success of direct antivirals in curing hepatitis C, there are concerns about resistance to the drugs.
Liver Transplant: Ribavirin Not Necessary to Prevent HCV Recurrence
Nov 14, 2015 | AASLD 2015 | Gale Scott
Liver transplant specialists looked at whether post-transplant hepatitis C patients could safely eliminate ribavirin (RBV) from their drug regimens. They found they could.
Liver Transplant Lists Grow Shorter
Nov 14, 2015 | AASLD 2015 | Gale Scott
Ever since direct acting antivirals for hepatitis C came on the scene, physicians have been watching to see if the need for liver transplants will diminish. It appears they have.
Chinese Study Finds Cheaper, Shorter HCV Drug Regimen
Nov 14, 2015 | AASLD 2015 | Gale Scott
Most patients with non-cirrhotic livers and HCV infection may need only three weeks of direct-acting antivirals, researchers said. They reported on a small proof-of-concept study in China.
Gilead Presents New Data at The Liver Meeting 2015 - Investigational Compounds for Chronic Hepatitis B and Liver Fibrosis
AASLD - AbbVie Announces New Data on VIEKIRA PAK®\
One-step test for hepatitis C virus infection developed by UC Irvine Health researchers
Medicaid denies half of prescriptions for new hepatitis C drugs
Conatus Pharmaceuticals Announces Selection of Late-Breaking Oral Presentation as Noteworthy Abstract to be Highlighted in AASLD President's Press Conference at AASLD Annual Meeting
FDA Approves New Indications for Harvoni®, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Harvoni® (ledipasvir/sofosbuvir) for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus (HCV) infection and in patients co-infected with HIV. In addition, Harvoni plus ribavirin (RBV) for 12 weeks was approved as an alternate therapy to 24 weeks of Harvoni for treatment-experienced, genotype 1 patients with cirrhosis. Harvoni received regulatory approval for the treatment of chronic HCV genotype 1 infection in adults in the United States in October 2014.
As NJ’s heroin epidemic grows, potentially deadly hepatitis C spreads
As the heroin epidemic continues in New Jersey, an infectious disease specialist is finding that a growing number of heroin users are testing positive for a potentially deadly virus they don’t even know they had.
Is cure of hepatitis C with medications possible?
What defines a cure?
By Donald Jensen, MD
The term ‘cure’ is such a powerful word with such important implications that liver specialists and virologists avoided using it for decades to describe one outcome of hepatitis C therapy (WebMD)...
The Latest Hepatitis C News at the Annual Liver Meeting
The 66th annual Liver Meeting begins tomorrow. Sponsored by the American Association for the Study of Liver Diseases (AASLD), it is the premier event devoted to liver health in the U.S. I am confident that the meeting will be packed with not-to-be-missed hepatitis C information. To stoke your appetite, here’s information about a much anticipated hepatitis C treatment that will likely be discussed at the meeting...
Best of the International Liver Congress 2015: Focus on Fatty Liver
Gastroenterology & Endoscopy News asked two experts to discuss some of the most newsworthy research related to fatty liver disease presented at the meeting. Compiled and written by David Wild.
Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis
Previous studies have demonstrated that coffee consumption may be inversely correlated with hepatic fibrosis and cirrhosis. However, the reported results have been inconsistent. To summarize previous evidences quantitatively, a meta-analysis was performed.
This Is Why Hepatitis C Drugs Are So Expensive
Firms that have risked millions (or perhaps even billions) to develop and test a drug in large-scale trials want to recoup that investment, and then some. For instance, Gilead Sciences, which manufactures Sovaldi, spent $11 billion in 2011 to acquire Pharmasset Inc., the pharmaceutical company that invented the drug in the first place.
Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012
Trial disclosures for new drugs remain below legal and ethics standards, with wide variation in practices among drugs and their sponsors. Best practices are emerging. 2 of our 10 reviewed companies disclosed all trials and complied with legal disclosure requirements for their 2012 approved drugs. Ranking new drugs on transparency criteria may improve compliance with legal and ethics standards and the quality of medical knowledge
Changes Afoot at The Liver Meeting
On the other hand, what hasn't changed is the continued focus on hepatitis C (HCV) and fatty liver disease
Knowns and unknowns of US drug pricing
$14 Million PCORI Research Grant Awarded to Montefiore and Einstein to Fund Hepatitis C Research
Faster, Cheaper Hep C Cures on the Horizon?
CMS Enters Pricey Hepatitis C Drug Debate
The Centers for Medicare & Medicaid Services recently sent letters to Medicaid directors of all 50 states, as well as to AbbVie, Gilead Sciences Inc., Johnson & Johnson and Merck & Co.
Template and white paper for State Insurance Commissioners re: HCV Tx Access
Attached is a template for advocates to use to reach out directly to your State Insurance Commissioner re: Removing Illegal Restrictions to Access to Hepatitis C Treatment. This document was shared with us by Hepatitis Education Project.
Addenbroooke's consultant hails drugs announcement for hepatitis patients a ...
An Addenbrooke's consultant has welcomed the news that new drugs are to be funded by the NHS to treat the majority of adult patients with chronic hepatitis C. Hepatitis C patients in England and Wales will soon be able to be treated with a new once day ...
UIS researchers studying Hepatitis C among homeless
Five hundred dollars may seem a paltry sum for a crowdfunding effort these days. But the $500 being sought by University of Illinois Springfield researchers will be used for research that could save lives and thousands of dollars in treatment costs for ...
Type 2 Diabetes Patients Fall Into Three Groups, Say Scientists
Knowing where a patient fits, based on genotype and risk for comorbidities, may inform future medication use and treatments, the researchers suggest.
Antivirals May Reduce the Need for Recurrent Transplants in HCV
Grazoprevir, Elbasvir Combination Effective for Patients With Hepatitis C, Kidney Disease: Presented at Kidney Week
President of Malta presents €1.2 million worth of Hepatitis C medication to government
An Early Hepatitis C Thanksgiving Blessing
Information Update - Risk of Serious Liver Injury associated
with Hepatitis C Treatments: Holkira Pak and Technivie
OTTAWA, Nov 10, 2015 /CNW/ - In response to new international safety information, Health Canada is advising Canadians that it is working with the manufacturer of Holkira Pak and Technivie to update drug labels (product monographs) to include new information regarding serious liver injury.
Nov 2015 HCV Newsletter and Blog Updates
Greetings everyone, welcome to this months index of Newsletters, blog and publication updates.
Gilead's Sovaldi Tied to Slow Heartbeat in Hepatitis C Patients
Gilead Sciences Inc.’s blockbuster hepatitis C medicine Sovaldi may trigger an abnormally slow heartbeat and put patients at risk of passing out, according to French doctors who said treatments containing the drug should be used with caution.
Therapy With Direct-Acting Antivirals for Genotype 3 Patients:
Interferon's Last Gasp? Commentary
Hepatitis C virus (HCV) genotypes (GTs) 2 and 3 account for approximately 40% of infections by this virus worldwide.1 Patients with HCV GT3 have more rapid disease progression and are less responsive to treatment than those with GT2,2 and GT3 infection is considered relatively difficult to cure with the available direct-acting antivirals (DAAs).
Harvoni for Acute Hepatitis C
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (SWIFT-C)
Interferon Makes a Comeback for Tough-to-Treat HCV
by Bridget M. Kuehn
People with genotype 3 hepatitis C virus (HCV), cirrhosis and a history of unsuccessful treatment are among the most challenging for clinicians to manage. Howe ver, results of a recent clinical trial suggest an unlikely answer to this clinical conundrum: adding pegylated interferon (PEG) to a 12-week regimen of sofosbuvir (Harvoni, Gilead) and ribavirin (SOF+RBV).
Innovative Calculator Tool Giving Insight into the Costs of Hepatitis C beyond Anti-Virals
Primrose Healthcare has just launched an innovative calculator tool to help health insurers and other payers uncover and better understand the total costs associated with the hepatitis C virus (HCV) within their populations.
Disease burden of chronic hepatitis C among immigrants
The most recent issue of the Journal of Viral Hepatitis investigates the disease burden of chronic hepatitis C among immigrants in Canada.
Find Way to Focus on Dietary Supplement Safety, Experts Say
A former principal deputy commissioner of the U.S. Food and Drug Administration is proposing a solution to the current gridlock over the regulation of dietary supplements: Focus less on whether these vitamins, minerals and herbal extracts actually do what they claim and instead take important steps to improve their safety.
Medicaid officials want to expand access to pricey hepatitis C drug
Health care officials in Washington state thought thousands of Medicaid patients would line up to receive a breakthrough hepatitis C treatment that went on the market late last year.
Weekend Reading: AASLD 2015 Key Abstracts and Treatment of HCV Genotype 3: Where are we now?
Gilead Submits NDA to U.S. FDA for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi® in December 2013, and velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection. The NDA is supported by clinical studies exploring the use of 12 weeks of SOF/VEL for patients with genotype 1-6 HCV infection, including patients with compensated cirrhosis and 12 weeks of SOF/VEL with ribavirin for patients with decompensated cirrhosis.
Where is last month's news?
HCV News Digest 2015
HCV News Digest
Hepatitis C Newsletters
These links will take you to the premier Hepatitis C sites and keep you informed with breaking news, clinical studies, new drugs, podcasts, newsletters, support, personal experiences and more.
Email - email@example.com
Reducing the cost of new hepatitis C drugs
An index of articles pointing the reader to the current controversy over the high price of Sovaldi, Harvoni (ledipasvir/sofosbuvir) and AbbVie Viekira Pak.
Where Can I find a specialist to treat HCV?
Find a Specialist In Your Area
Testing, Diagnosis and Treatment
Are you struggling to afford the costs of Hepatitis C treatments? A new program through the HealthWell Foundation may be able to help.
Patient Assistance Programs
Financial support - updated to include Daklinza and TECHNIVIE
Approved Treatments for Hepatitis C updated to include
Daklinza and TECHNIVIE
Drug Pipeline – Quick Reference Guides
To learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.
Hepatitis Clinical Trials Listed By State
A listing of Hepatitis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
ClinicalTrials.gov: updated in the last 30 days
Daklinza (daclatasvir) in Combination with Sofosbuvir for HCV Genotype 3
Package Insert, patient information with news and updates
TECHNIVIE (ombitasvir, paritaprevir, ritonavir)
TECHNIVIE, a fixed-dose combination containing ombitasvir, paritaprevir, and ritonavir in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis.
Package Insert, patient information with news and updates
U.S. FDA Approves Gileads Harvoni (Ledipasvir/Sofosbuvir)
Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.
Both drugs in Harvoni interfere with the enzymes needed by HCV to multiply. Sofosbuvir is a previously approved HCV drug marketed under the brand name Sovaldi. Harvoni also contains a new drug called ledipasvir.
Research and Updates
FDA approves Olysio (simeprevir) in combination with Gilead Sciences' Sovaldi (sofosbuvir)
FDA Approves AbbVie Combo Hepatitis C Treatment
On December 19, 2014, FDA approved VIEKIRA Pak (ombitasvir, paritaprevir, ritonavir fixed dose combination tablets copackaged with dasabuvir tablets) for use with or without ribavirin for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.
AbbVie Viekira Pak Homepage
AbbVie Viekira Pak - News, Research and financial support
ABBVIE 'VIEKIRA PAK' - HIGHLIGHTS OF PRESCRIBING INFORMATION
Gilead's Sovaldi (Sofosbuvir) FDA Approved
Sovaldi is approved in HCV genotypes 1 and 4, treatment-naïve adults in combination with PEG-IFN and ribavirin and the first approved interferon-free treatment regimen for people with HCV genotypes 2 and 3. Overall cure rates are at 80%, response rates and treatment duration varies, depending on genotype, viral and host factors.
Sovaldi (sofosbuvir) - Prescribing And Medication Guides
For detailed information please see Sovaldi (sofosbuvir) - Summary of the basis of approval and highlights from prescribing information and download sofosbuvir FDA review package.
OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
Important Safety Information
HCV Drug Interaction Charts
Provides a clinically useful, reliable, comprehensive, up-to-date, evidence-based drug-drug interaction resource, freely available to healthcare workers, patients and researchers.
Need To Talk To Someone ?
Patient Advocate Foundation Offers New CareLine for Hepatitis C Patients
Hepatitis C CareLine, providing individualized, sustained assistance to patients diagnosed with Hepatitis C. The CareLine will provide help to patients across the country to resolve healthcare access and insurance issues, at no charge to the patient.